$25.35-1.08 (-4.09%)
Kestra Medical Technologies, Ltd.
Kestra Medical Technologies, Ltd. in the Healthcare sector is trading at $25.35 with a market capitalization of $1.1B. Wall Street consensus targets $27.71 (7 analysts), implying a +9.3% move over the next 12 months. The stock is currently 15% below its 52-week high of $30.00, remaining 8.1% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $24.55Mβ | $22.57Mβ | $19.37Mβ | $17.23Mβ | $15.09M |
| Gross Profit | $12.91Mβ | $11.42Mβ | $8.85Mβ | $7.63Mβ | $6.55M |
| Operating Income | -$34.77Mβ | -$31.75Mβ | -$28.88Mβ | -$48.21Mβ | -$20.60M |
| Net Income | -$34.17Mβ | -$32.78Mβ | -$25.83Mβ | -$52.05Mβ | -$21.51M |
Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitiv...
Kestra Medical Technologies (KMTS) has drawn investor attention after recent trading left the stock about 23% lower over the past month and roughly 28% lower over the past 3 months. See our latest analysis for Kestra Medical Technologies. With the share price at US$19.46, the stock has a 7 day share price return of 1.9%. However, the 30 day and year to date share price returns of about 23% and 20% declines point to fading short term momentum, despite a 1 year total shareholder return of...
Kestra Medical Technologies (NASDAQ:KMTS) reported what management described as a strong third quarter of fiscal 2026, highlighted by higher prescriptions, accelerating revenue growth, and continued gross margin expansion as the company scales its wearable cardioverter defibrillator (WCD) business a
Moby summary of KESTRA MEDICAL TECHNOLOGIES, LTD.'s Q3 2026 earnings call
Kestra Medical Technologies Ltd (KMTS) reports a 63% revenue increase, despite ongoing net losses and strategic investments in market expansion.
This article first appeared on GuruFocus. Kestra Medical Technologies Ltd (NASDAQ:KMTS) is set to release its Q3 2026 earnings on Mar 17, 2026. The consensus estimate for Q3 2026 revenue is $22.86 million, and the earnings are expected to come in at -$0.60 per share.